Endurant Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-27,992
| Closed | -$2.73M | – | 61 |
|
|
2022
Q2 | $2.73M | Buy |
+27,992
| New | +$2.73M | 0.96% | 25 |
|
|
2017
Q1 | – | Sell |
-11,500
| Closed | -$445K | – | 94 |
|
|
2016
Q4 | $445K | Sell |
11,500
-700
| -6% | -$27.1K | 0.18% | 64 |
|
|
2016
Q3 | $618K | Sell |
12,200
-1,900
| -13% | -$96.2K | 0.23% | 70 |
|
|
2016
Q2 | $641K | Buy |
14,100
+1,000
| +8% | +$45.5K | 0.21% | 70 |
|
|
2016
Q1 | $518K | Buy |
+13,100
| New | +$518K | 0.17% | 68 |
|
|
2015
Q3 | – | Sell |
-14,900
| Closed | -$712K | – | 87 |
|
|
2015
Q2 | $712K | Buy |
+14,900
| New | +$712K | 0.21% | 75 |
|